



Article

Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study

Sven H. Loosen ^{1,*}, Alexander Killer ^{1,*}, Hans Henrich Bock ¹, Tom Luedde ¹, Christoph Roderburg ¹ and Karel Kostev ²

¹ Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany; hans.bock@med.uni-duesseldorf.de (H.H.B.); tom.luedde@med.uni-duesseldorf.de (T.L.); christoph.roderburg@med.uni-duesseldorf.de (C.R.)

² Epidemiology, IQVIA, 60549 Frankfurt, Germany

* Correspondence: sven.loosen@med.uni-duesseldorf.de (S.H.L.); alexander.killer@med.uni-duesseldorf.de (A.K.)

† These authors share first authorship.

‡ These authors share senior authorship.

Abstract: Background: Osteoporosis and bone fractures affect health and quality of life. Since bone disease is multifactorial, identifying risk factors is key in prevention. There are multiple reports on how viral hepatitis, especially chronic hepatitis B (CHB) and chronic hepatitis C (CHC), are affecting bone disease, but results vary. Here, we analyzed the potential association between CHB/CHC and osteoporosis or bone fractures in a large outpatient cohort in Germany. **Methods:** We included 3136 outpatients with CHB and 15,608 matched non-hepatitis individuals as well as 2867 outpatients with CHC and 14,335 matched non-hepatitis individuals from the Disease Analyzer Database between 2005 and 2022. The main outcome was the 5-year cumulative incidence of osteoporosis and bone fractures as a function of either CHB or CHC. **Results:** Within 5 years of the index date, 2.9% vs. 1.6% of patients with and without CHB were diagnosed with osteoporosis ($p = 0.001$) and 1.0% vs. 0.4% were diagnosed with bone fractures ($p < 0.001$). Moreover, 3.3% of CHC patients and 2.2% of individuals without hepatitis C were diagnosed with osteoporosis ($p = 0.002$). In Cox regression analyses, CHB was significantly associated with an increased risk for osteoporosis (HR: 1.76) and fractures (HR:2.43) and CHC with osteoporosis (HR: 1.54). For both CHB and CHC, the association with osteoporosis was restricted to the female subgroup. **Conclusions:** CHB and CHC are associated with osteoporosis in women. CHB in male patients is associated with a higher risk of fractures. More research is needed to understand the underlying pathophysiological mechanisms.



Citation: Loosen, S.H.; Killer, A.; Bock, H.H.; Luedde, T.; Roderburg, C.; Kostev, K. Association between Chronic Hepatitis B/C and Incidence of Osteoporosis and Bone Fractures: Results from a Retrospective Cohort Study. *J. Clin. Med.* **2024**, *13*, 6152. <https://doi.org/10.3390/jcm13206152>

Academic Editors: Angela Quirino and Nadia Marascio

Received: 13 September 2024

Revised: 3 October 2024

Accepted: 9 October 2024

Published: 16 October 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: viral hepatitis; HBV; HCV; CHC; CHB; osteopenia; osteoporosis; virus; infection; regression

1. Introduction

Osteoporosis is a major risk factor for fractures, reduced quality of life and mortality [1,2]. Due to its high prevalence in older societies, it is already a disease of major importance and cases are expected to increase further in the future [3]. Therefore, the assessment of risk factors for osteoporosis in terms of prevention and screening is of key importance to reduce the further increase in disease burden. The main risk factors for osteoporosis are female gender and age [4], while the modifiable factors are smoking, BMI, physical activity and diet, especially calcium and vitamin D intake [5]. Osteoporosis supposedly affects 22 million women and 5.5 million men in the European union [6] and 800,000 fractures occur in Germany per year [7].

As we know from the gastroenterologist's point of view, bone density is linked to liver health [8]. In patients with liver disease, bone disease is particularly common in the

cirrhosis stage but can also occur at earlier stages. On the other hand, there is growing evidence that sarcopenia in patients with liver cirrhosis is a major factor for mortality, so immobility caused by fractures should be avoided [9], as this can lead to a vicious circle for patients with osteoporosis [10].

In addition, there is growing interest in the interaction between bone and liver, known as the liver–bone axis [11]. As the liver plays a central role in metabolism and hormonal status, the effects of liver disease on osteoporosis are being investigated based on changes in individual proteins/hormones produced by the liver. The proteins/hormones involved in communication between the liver and bone growth and whose serum levels are affected by liver disease include, for example, insulin-like growth factor 1, fibroblast growth factor 21 and lecithin–cholesterol acyltransferase [12]. As a result of impaired liver function, the reported prevalence of osteoporosis in cirrhotic patients is very high at 20 to 50% [13]. For viral hepatitis, chronic inflammation, in particular, is considered to be responsible for osteoclast activation regardless of the stage of liver fibrosis/cirrhosis [11].

One of the main causes of liver disease worldwide is viral hepatitis, primarily the hepatitis B virus (HBV) and the hepatitis C virus (HCV) [14]. Hepatitis B is transmitted during birth (vertical transmission), sexual contact and blood contact. While 90% of infections are acute, around 10% of infections lead to a chronic course defined as remaining positive for hepatitis B virus for six months [15,16]. Patients with chronic hepatitis and elevated transaminases, liver fibrosis/cirrhosis, high viral load and pregnancy or immune-suppressive treatments are treated with nucleos(t)id analogs to prevent disease progression [15]. Hepatitis C is mostly transmitted by blood via drug use or in health care settings or by sexual contact and leads to a chronic course in 80% of patients [17], also defined as six months of infection [18]. Viral hepatitis also remains an important cause of liver disease in Europe, albeit with a decreasing trend [19]. In Germany, 0.2–0.7% of the general population are HBsAg-positive (meaning having active hepatitis B infection), 0.2–1.9% are anti-HCV-positive and 0.2–0.4% are HCV RNA-positive [20].

We know about associations between HBV and HCV and developing osteoporosis and fractures [21–25], but there are varying results in terms of the strength of association. With regard to HBV and osteoporosis, there is also debate as to whether antiviral treatment, particularly with tenofovir disoproxil fumarate (TDF), promotes the development of osteoporosis compared to other antiviral drugs or patients without treatment [24,26,27].

As HCV treatment has improved dramatically since the introduction of direct antiviral drugs and most of the data we have come across on viral hepatitis and bone disease are from the 2010s, we wanted to re-examine the relationship between viral hepatitis and osteoporosis/fractures in the era of modern antiviral therapy in a high-income country.

2. Patients and Methods

2.1. Database

This study was based on the Disease Analyzer database (IQVIA), which contains data on drug prescriptions, diagnoses and basic medical and demographic data obtained directly in an anonymous format from computer systems used in the practices of general practitioners and specialists [28]. The database covers approximately 2500 outpatient practices in Germany. It has previously been shown that the panel of practices included in the Disease Analyzer database is representative of general and specialized practices in Germany [28]. Finally, this database has already been used in previous studies focusing on hepatitis [29] and osteoporosis [30,31].

2.2. Study Population

This retrospective cohort study included adult patients (≥ 18 years) with an initial diagnosis of chronic hepatitis including chronic hepatitis B (CHB, ICD-10: B18.0, B18.1) and chronic hepatitis C (CHC, ICD-10: B18.2) from 1293 general practices in Germany between January 2005 and December 2022 (index date; Figure 1). Patients were only included when they had at least 12 months of pre-observation time prior to the index date. Patients with

a diagnosis of osteoporosis (ICD-10: M80, M81) or a documented bone fracture (ICD-10: S02, S12, S22, S32, S42, S52, S62, S72, S82, S92, T02, T08, T10, T12) prior to or at the index date were excluded. Hepatitis patients were matched to individuals without a history of liver diseases by nearest-neighbor propensity scores based on sex, age, index year, obesity, diabetes and yearly consultation frequency. Diabetes and obesity were used as they are associated with osteoporosis and fractures. As hepatitis patients have a much higher GP consultation frequency, and higher consultation frequency can increase the probability of other diagnoses, we also included the consultation frequency per year in the propensity matching. For the non-hepatitis cohort, the index date was that of a randomly selected visit between January 2005 and December 2022 (Figure 1). Each kind of hepatitis was compared with accordingly matched non-hepatitis individuals. Cohorts were considered to be adequately balanced if the absolute value of the standardized mean difference for each covariate was 0.25 or less.




Figure 1. Selection of study patients.

2.3. Study Outcomes and Covariates

The main outcome of the study was the 5-year cumulative incidence of osteoporosis and bone fractures as a function of either chronic hepatitis B or C. As we were unable to differentiate between osteoporotic and non-osteoporotic fractures, we only consider fractures in patients who were also diagnosed with osteoporosis.

2.4. Statistical Analyses

Differences in the sample characteristics between patients with and without chronic hepatitis were tested using the Wilcoxon signed-rank test for continuous variables, the McNemar test for categorical variables with two categories and the Stuart–Maxwell test

for categorical variables with more than two categories. The cumulative incidence of osteoporosis and fractures was evaluated using Kaplan–Meier curves. Cox regression models were conducted to study the association between CHB or CHC and the incidence of osteoporosis and/or bone fractures. Regression analyses were performed separately for women and men. No age-stratified analyses were conducted as the proportion of osteoporosis diagnosis in the age group < 50 years was too small for subgroup analysis. To counteract the problem of multiple comparisons (8 regression models), a *p*-value < 0.005 was considered statistically significant. Analyses were carried out using SAS version 9.4 (SAS institute, Cary, NC, USA).

3. Results

3.1. Baseline Characteristics

The present study included 3136 patients with CHB and 15,608 matched non-hepatitis individuals. Moreover, in a second cohort, we included 2867 patients with CHC and 14,335 matched non-hepatitis individuals. The baseline characteristics of the study cohort are shown in Table 1. The mean age [SD] was 50.2 [14.6] years in the CHB cohort and 50.8 [14.6] in the CHC cohort. A total of 52.7% of patients in the CHB cohort and 60.7% of patients in the CHC cohort were female. Due to the matched pair study design, no significant differences between variables were observed between the two hepatitis cohorts and their matched non-hepatitis cohorts.

Table 1. Basic characteristics of the study sample (after 1:5 matching).

| Variable | Proportion Affected among Patients with Chronic Hepatitis (N, %) | Proportion Affected among Patients without Chronic Hepatitis (N, %) | <i>p</i> -Value |
|-------------------------------|--|---|-----------------|
| Hepatitis B | | | |
| N | 3136 | 15,680 | |
| Age (Mean, SD) | 50.2 (14.6) | 50.1 (14.6) | 0.945 |
| Age ≤ 40 | 855 (27.3) | 4278 (27.3) | 0.995 |
| Age 41–50 | 763 (24.3) | 3799 (24.2) | |
| Age 51–60 | 757 (24.1) | 3766 (24.0) | |
| Age > 60 | 761 (24.5) | 3837 (24.5) | |
| Men (%) | 1485 (47.3) | 7394 (47.2) | 0.840 |
| Women (%) | 1651 (52.7) | 8286 (52.8) | |
| Diabetes | 541 (17.3) | 2685 (17.1) | 0.863 |
| Obesity | 397 (12.7) | 2004 (12.8) | 0.853 |
| Yearly consultation frequency | 6.4 (4.1) | 6.4 (4.1) | 0.746 |
| Hepatitis C | | | |
| N | 2867 | 14,335 | |
| Age (Mean, SD) | 50.8 (14.6) | 50.8 (14.6) | 0.959 |
| Age ≤ 40 | 766 (26.7) | 3853 (26.9) | 0.994 |
| Age 41–50 | 737 (25.7) | 3662 (25.6) | |
| Age 51–60 | 685 (23.9) | 3,405 (23.7) | |
| Age > 60 | 679 (23.7) | 3415 (23.8) | |


Table 1. Cont.

| Variable | Proportion Affected among Patients with Chronic Hepatitis (N, %) | Proportion Affected among Patients without Chronic Hepatitis (N, %) | p-Value |
|-------------------------------|--|---|---------|
| Hepatitis C | | | |
| Men (%) | 1143 (39.9) | 5706 (39.8) | 0.950 |
| Women (%) | 1724 (60.1) | 8629 (60.2) | |
| Diabetes | 434 (15.2) | 2158 (15.1) | 0.909 |
| Obesity | 218 (7.6) | 1074 (7.5) | 0.836 |
| Yearly consultation frequency | 7.2 (4.5) | 7.2 (4.5) | 0.932 |

3.2. Association of CHB and a Subsequent Diagnosis of Osteoporosis and Bone Fractures


Within 5 years of the index date, 2.9% of CHB patients and 1.6% of individuals without hepatitis were diagnosed with osteoporosis (log-rank, $p = 0.001$). In terms of bone fractures, 1.0% of the CHB patients but only 0.4% of the non-hepatitis patients were diagnosed with bone fractures (log-rank, $p < 0.001$, Figure 2). The most frequent fractures were shoulder and arm (33.9% in CHB, 34.1% in CHC and 33.9% in those without hepatitis), followed by foot and leg (23.4% in CHB, 22.5% in CHC and 27.6% in those without hepatitis) and ribs (15.6% in CHB, 19.1% in CHC and 17.0% in those without hepatitis).

In Cox regression analyses, CHB was significantly associated with an increased risk of osteoporosis (hazard ratio (HR): 1.76; 95% CI: 1.31–2.36) as well as bone fractures (HR: 2.43; 95% CI: 1.42–4.14). The association between CHB and osteoporosis reached the predefined level of statistical significance in women only (HR: 1.92; 95% CI: 1.38–2.69). Contrarily, the association between CHB and bone fractures was only significant in men (HR: 3.42; 95% CI: 1.44–8.12).



(A)

Figure 2. Cont.




(B)

Figure 2. Kaplan–Meier curves showing the incidence of osteoporosis (A) and bone fractures (B) between patients with and without chronic HBV.


3.3. Association of CHC and a Subsequent Diagnosis of Osteoporosis and Bone Fractures

Within 5 years of the index date, 3.3% of CHC patients and 2.2% of individuals without hepatitis were diagnosed with osteoporosis (log-rank, $p = 0.002$). Moreover, 0.9% of CHC patients and 0.7% of the non-hepatitis patients were diagnosed with a bone fracture (log-rank, $p = 0.489$, Figure 2). In regression analyses, CHC was significantly associated with an increased risk of osteoporosis (HR: 1.54; 95% CI: 1.17–2.02, Figure 3). In contrast, CHC was not associated with an increased risk of bone fractures (HR: 1.21; 95% CI: 0.71–2.06, Figure 3). Interestingly, the association between CHC and osteoporosis was only significant in women (HR: 1.75; 95% CI: 1.29–2.37) but not men (Table 2).



(A)

Figure 3. Cont.



(B)

Figure 3. Kaplan–Meier curves showing the incidence of osteoporosis (A) and bone fractures (B) between patients with and without chronic HCV.

Table 2. Association between hepatitis B and C and the incident osteoporosis and fracture diagnoses in patients followed in general practices in Germany (Cox regression models).

| | Hepatitis vs. No Hepatitis (HR, 95% CI) | | |
|---|---|--------------------|--------------------|
| | Total | Women | Men |
| Hepatitis B versus no liver diseases | | | |
| Outcome: Incidence of osteoporosis | 1.76 (1.31–2.36) * | 1.92 (1.38–2.68) * | 1.29 (0.70–2.40) |
| Outcome: Incidence of bone fractures | 2.43 (1.42–4.14) * | 1.95 (0.99–3.88) | 3.42 (1.44–8.12) * |
| Hepatitis C versus no liver diseases | | | |
| Outcome: Incidence of osteoporosis | 1.54 (1.17–2.02) * | 1.75 (1.29–2.37) * | 0.97 (0.51–1.86) |
| Outcome: Incidence of bone fractures | 1.21 (0.71–2.06) | 1.25 (0.69–2.26) | 1.05 (0.30–3.69) |

* $p < 0.005$.

4. Discussion

In the present study, we evaluate a potential association between CHB and CHC and a subsequent diagnosis of osteoporosis or bone fractures in a large real-world cohort of CHC/CHB patients in Germany. We observe that CHB was significantly associated with an increased risk of osteoporosis and fractures and CHC with osteoporosis. Thereby, we confirm previous findings that CHB is associated with osteoporosis. A Korean study from 2019 compared the odds ratio for diagnosis of CHB or CHC in patients with osteoporosis and a matched control group [25]. Similar to our data, the association between CHB and osteoporosis was stronger than between CHC and osteoporosis. Furthermore, as in our data, the association was limited to the female subgroup. Tao et al. analyzed data from the US NHANES database for association of HBsAg-positive and HCV RNA-positive patients and lower bone mineral density and found positive relations for both [22]. A meta-analysis of 15 studies regarding HIV/HCV-coinfected patients showed a HR of 1.63 for coinfecting patients compared to HIV mono-infected patients for the diagnosis of osteoporosis [32].

Our data show differing effects of viral hepatitis and sex. The HR for osteoporosis was 1.92 in women with CHB and 1.75 in those with CHC, while in men, there was no

statistically significant association. This is somewhat counterintuitive, as CHB is known to affect liver health more in men than women. Men are more likely to develop HCC, less likely to clear HBeAg and less likely to be protected by HBV vaccination [33]. For HCV infection, there are also known gender differences: Women are more likely to clear HCV infections and progress slower towards cirrhosis [34]. Analysis of immune response and cytokine markers may help to explain the different effect on bone disease. Since our analysis did not include any immune or inflammatory markers, we encourage further research on this matter. Primary osteoporosis is in general more prevalent in women than in men, while secondary osteoporosis is in general more frequent in men, which is contrary to our result [35].

The significant higher hazard ratio/prevalence of osteoporosis in female patients could lead to larger patient samples for that subgroup and explain why differences are only statistically significant for women.

Of note, the association between CHB and fractures was only significant in men with an HR of 3.42 in the reported data of our study. In contrast, we could only find a non-significant association between CHB and osteoporosis in men. Therefore, it seems likely that fractures were not related to osteoporosis and probably more frequent in male CHB patients because of confounders that were not analyzed. For example, one confounder leading to more fracture risk could be alcohol consumption, which is also reported to be an important factor for patients with HBV infection in terms of liver disease progression [36,37]. In conclusion, we did find significant differences between sexes but a lack of more data prevents us from explaining the differences.

As a clinical consequence of our research and already published data, patients with chronic HBV and/or HCV should be screened for risk of osteoporosis and this risk should be addressed in patient communication. Following recommendations for osteoporosis screening, bone mineral density testing should be carried out for all patients aged 50 with risk factors for fracture/osteoporosis [38]. Diagnosis of osteoporosis and the following treatment reduces the risk for following fractures underlining the importance of screening [38].

Lifestyle factors like smoking or physical exercise should be optimized, since they do not only affect risk for osteoporosis but also risk of liver disease progression. In particular, the importance of alcohol intake in progression to cirrhosis and its negative impact on bone health should be emphasized [39,40]. Patients should also be evaluated for vitamin D supplementation and/or guided for improvement of diet choices. Also, comedication that can worsen development of osteoporosis or fractures such as proton pump inhibitors [41] or benzodiazepines [42], for example, should be evaluated for cessation.

By study design, this study is limited because of its retrospective nature. Furthermore, we cannot differentiate between treated and untreated patients, meaning we can only report associations between diagnosis of viral hepatitis and osteoporosis or fractures. Since antiviral treatment of HBV reportedly affects risk of osteoporosis, this is further limiting. A major limit for analysis of HCV-positive patients is that we cannot differentiate between cured and not cured patients. We also cannot match lifestyle factors such as physical exercise, BMI, alcohol intake or smoking. Smoking is, for example, more frequent in HCV patients than in the general population [43,44]. In an American study, hepatitis C-positive people were almost three times more likely to smoke than hepatitis C-negative people [45]. Finally, sufficient information on the presence of liver cirrhosis was not available, so we were unable to differentiate between patients with and without liver cirrhosis.

5. Conclusions

Our study supports prior data on the association between chronic viral hepatitis and development of osteoporosis. We report differences between female and male patients that need further research. Also, changes in risk for osteoporosis after finite antiviral treatment for hepatitis C should be evaluated. Hepatologists and general practitioners treating patients with viral hepatitis should take note of the osteoporosis risk and evaluate screening, prevention and treatment of osteoporosis.

Author Contributions: S.H.L., K.K. and C.R. designed the study, K.K. performed statistical analyses and generated figures and tables, A.K., S.H.L. and K.K. wrote the manuscript and H.H.B. and T.L. provided intellectual input. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Ethical review and approval were waived for this study due to the nature of the “Disease Analyzer” database, which was used for analysis. It contains anonymized electronic patient records. Patient data was analyzed in aggregated form without individual data being available. An individual consent form was not obtained following national and European legislation.

Informed Consent Statement: Patient consent was waived due to the retrospective and anonymous data-collection without individual data.

Data Availability Statement: The underlying data are available upon reasonable request from the corresponding author.

Conflicts of Interest: The authors declare no competing interests. A.K. did lectures for Gilead, received a travel bursary from Gilead, Ipsen and Abbvie and a research grant from Gilead. T.L. and H.H.B. received consulting fees from Gilead, Abbvie and Ipsen and payment or honoraria for lectures or presentations from Gilead and Abbvie. K.K. works for IQVIA.

References

1. Stanghelle, B.; Bentzen, H.; Giangregorio, L.; Pripp, A.H.; Bergland, A. Associations between health-related quality of life, physical function and pain in older women with osteoporosis and vertebral fracture. *BMC Geriatr.* **2019**, *19*, 298. [[CrossRef](#)] [[PubMed](#)]
2. Bliuc, D.; Nguyen, N.D.; Alarkawi, D.; Nguyen, T.V.; Eisman, J.A.; Center, J.R. Accelerated bone loss and increased post-fracture mortality in elderly women and men. *Osteoporos. Int.* **2015**, *26*, 1331–1339. [[CrossRef](#)]
3. Cooper, C.; Cole, Z.A.; Holroyd, C.R.; Earl, S.C.; Harvey, N.C.; Dennison, E.M.; Melton, L.J.; Cummings, S.R.; Kanis, J.A. Secular trends in the incidence of hip and other osteoporotic fractures. *Osteoporos. Int.* **2011**, *22*, 1277–1288. [[CrossRef](#)]
4. Pietschmann, P.; Rauner, M.; Sipos, W.; Kersch-Schindl, K. Osteoporosis: An age-related and gender-specific disease—A mini-review. *Gerontology* **2009**, *55*, 3–12. [[CrossRef](#)] [[PubMed](#)]
5. Dontas, I.A.; Yiannakopoulos, C.K. Risk factors and prevention of osteoporosis-related fractures. *J. Musculoskelet. Neuronal Interact.* **2007**, *7*, 268–272.
6. Kanis, J.A.; Norton, N.; Harvey, N.C.; Jacobson, T.; Johansson, H.; Lorentzon, M.; McCloskey, E.V.; Willers, C.; Borgström, F. SCOPE 2021: A new scorecard for osteoporosis in Europe. *Arch. Osteoporos.* **2021**, *16*, 82. [[CrossRef](#)]
7. O’Kelly, J.; Bartsch, R.; Kossack, N.; Borchert, J.; Pignot, M.; Hadji, P. Real-world effectiveness of osteoporosis treatments in Germany. *Arch. Osteoporos.* **2022**, *17*, 119. [[CrossRef](#)] [[PubMed](#)]
8. Danford, C.J.; Trivedi, H.D.; Bonder, A. Bone Health in Patients With Liver Diseases. *J. Clin. Densitom.* **2020**, *23*, 212–222. [[CrossRef](#)]
9. Tantai, X.; Liu, Y.; Yeo, Y.H.; Praktiknjo, M.; Mauro, E.; Hamaguchi, Y.; Engelmann, C.; Zhang, P.; Jeong, J.Y.; van Vugt, J.L.A.; et al. Effect of sarcopenia on survival in patients with cirrhosis: A meta-analysis. *J. Hepatol.* **2022**, *76*, 588–599. [[CrossRef](#)]
10. Kerr, C.; Bottomley, C.; Shingler, S.; Giangregorio, L.; de Freitas, H.M.; Patel, C.; Randall, S.; Gold, D.T. The importance of physical function to people with osteoporosis. *Osteoporos. Int.* **2017**, *28*, 1597–1607. [[CrossRef](#)]
11. Gao, H.; Peng, X.; Li, N.; Gou, L.; Xu, T.; Wang, Y.; Qin, J.; Liang, H.; Ma, P.; Li, S.; et al. Emerging role of liver-bone axis in osteoporosis. *J. Orthop. Translat.* **2024**, *48*, 217–231. [[CrossRef](#)] [[PubMed](#)]
12. Zhao, J.; Lei, H.; Wang, T.; Xiong, X. Liver-bone crosstalk in non-alcoholic fatty liver disease: Clinical implications and underlying pathophysiology. *Front. Endocrinol.* **2023**, *14*, 1161402. [[CrossRef](#)]
13. Goral, V.; Simsek, M.; Mete, N. Hepatic osteodystrophy and liver cirrhosis. *World J. Gastroenterol.* **2010**, *16*, 1639–1643. [[CrossRef](#)] [[PubMed](#)]
14. Stanaway, J.D.; Flaxman, A.D.; Naghavi, M.; Fitzmaurice, C.; Vos, T.; Abubakar, I.; Abu-Raddad, L.J.; Assadi, R.; Bhala, N.; Cowie, B.; et al. The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013. *Lancet* **2016**, *388*, 1081–1088. [[CrossRef](#)] [[PubMed](#)]
15. Terrault, N.A.; Lok, A.S.F.; McMahon, B.J.; Chang, K.-M.; Hwang, J.P.; Jonas, M.M.; Brown, R.S.; Bzowej, N.H.; Wong, J.B. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* **2018**, *67*, 1560–1599. [[CrossRef](#)] [[PubMed](#)]
16. Hyams, K.C. Risks of chronicity following acute hepatitis B virus infection: A review. *Clin. Infect. Dis.* **1995**, *20*, 992–1000. [[CrossRef](#)]
17. Roudot-Thoraval, F. Epidemiology of hepatitis C virus infection. *Clin. Res. Hepatol. Gastroenterol.* **2021**, *45*, 101596. [[CrossRef](#)]

18. Chen, S.L.; Morgan, T.R. The natural history of hepatitis C virus (HCV) infection. *Int. J. Med. Sci.* **2006**, *3*, 47–52. [[CrossRef](#)]
19. Cortesi, P.A.; Fornari, C.; Conti, S.; Antonazzo, I.C.; Ferrara, P.; Ahmed, A.; Andrei, C.L.; Andrei, T.; Artamonov, A.A.; Banach, M.; et al. Hepatitis B and C in Europe: An update from the Global Burden of Disease Study 2019. *Lancet Public Health* **2023**, *8*, e701–e716. [[CrossRef](#)]
20. Sperle, I.; Steffen, G.; Leendertz, S.A.; Sarma, N.; Beermann, S.; Thamm, R.; Simeonova, Y.; Cornberg, M.; Wedemeyer, H.; Bremer, V.; et al. Prevalence of Hepatitis B, C, and D in Germany: Results From a Scoping Review. *Front. Public Health* **2020**, *8*, 424. [[CrossRef](#)]
21. Wijarnpreecha, K.; Thongprayoon, C.; Panjawatanan, P.; Phatharacharukul, P.; Ungprasert, P. Hepatitis C virus infection and risk of osteoporosis: A meta-analysis. *Saudi J. Gastroenterol.* **2017**, *23*, 216–221. [[CrossRef](#)]
22. Tao, J.; Yan, Z.; Huang, W.; Feng, T. Seropositive for hepatitis B and C viruses is associated with the risk of decreased bone mineral density in adults: An analysis of studies from the NHANES database. *Front. Med.* **2023**, *10*, 1120083. [[CrossRef](#)]
23. Pelazas-González, R.; González-Reimers, E.; Alemán-Valls, M.R.; Santolaria-Fernández, F.; López-Prieto, J.; González-Díaz, A.; Gómez-Sirvent, J.L.; de La Vega-Prieto, M.J. Bone alterations in hepatitis C virus infected patients. *Eur. J. Intern. Med.* **2013**, *24*, 92–96. [[CrossRef](#)]
24. Yip, T.C.-F.; Lai, J.C.-T.; Yam, T.-F.; Tse, Y.-K.; Hui, V.W.-K.; Lai, M.S.-M.; Chan, H.L.-Y.; Wong, V.W.-S.; Wong, G.L.-H. Long-term use of tenofovir disoproxil fumarate increases fracture risk in elderly patients with chronic hepatitis B. *J. Hepatol.* **2024**, *80*, 553–563. [[CrossRef](#)]
25. Min, C.; Bang, W.J.; Kim, M.; Oh, D.J.; Choi, H.G. The association between hepatitis and osteoporosis: A nested case-control study using a national sample cohort. *Arch. Osteoporos.* **2019**, *14*, 34. [[CrossRef](#)]
26. Yang, X.; Yan, H.; Zhang, X.; Qin, X.; Guo, P. Comparison of renal safety and bone mineral density of tenofovir and entecavir in patients with chronic hepatitis B: A systematic review and meta-analysis. *Int. J. Infect. Dis.* **2022**, *124*, 133–142. [[CrossRef](#)]
27. Dessordi, R.; Watanabe, L.M.; Guimarães, M.P.; Romão, E.A.; de Lourdes Candolo Martinelli, A.; de Carvalho Santana, R.; Navarro, A.M. Bone loss in hepatitis B virus-infected patients can be associated with greater osteoclastic activity independently of the retroviral use. *Sci. Rep.* **2021**, *11*, 10162. [[CrossRef](#)]
28. Rathmann, W.; Bongaerts, B.; Carius, H.-J.; Kruppert, S.; Kostev, K. Basic characteristics and representativeness of the German Disease Analyzer database. *Int. J. Clin. Pharmacol. Ther.* **2018**, *56*, 459–466. [[CrossRef](#)]
29. Loosen, S.H.; Schöler, D.; Luedde, M.; Eschrich, J.; Luedde, T.; Kostev, K.; Roderburg, C. Differential role of chronic liver diseases on the incidence of cancer: A longitudinal analysis among 248,224 outpatients in Germany. *J. Cancer Res. Clin. Oncol.* **2023**, *149*, 3081–3087. [[CrossRef](#)]
30. Kostev, K.; Hadji, P.; Jacob, L. Impact of Osteoporosis on the Risk of Dementia in Almost 60,000 Patients Followed in General Practices in Germany. *J. Alzheimer's Dis. JAD* **2018**, *65*, 401–407. [[CrossRef](#)]
31. Stumpf, U.; Hadji, P.; van den Boom, L.; Böcker, W.; Kostev, K. Incidence of fractures in patients with type 1 diabetes mellitus—a retrospective study with 4420 patients. *Osteoporos. Int.* **2020**, *31*, 1315–1322. [[CrossRef](#)]
32. Dong, H.V.; Cortés, Y.I.; Shiau, S.; Yin, M.T. Osteoporosis and fractures in HIV/hepatitis C virus coinfection: A systematic review and meta-analysis. *AIDS* **2014**, *28*, 2119–2131. [[CrossRef](#)]
33. Wang, S.-H.; Chen, P.-J.; Yeh, S.-H. Gender disparity in chronic hepatitis B: Mechanisms of sex hormones. *J. Gastroenterol. Hepatol.* **2015**, *30*, 1237–1245. [[CrossRef](#)]
34. Baden, R.; Rockstroh, J.K.; Buti, M. Natural history and management of hepatitis C: Does sex play a role? *J. Infect. Dis.* **2014**, *209* (Suppl. S3), S81–S85. [[CrossRef](#)]
35. Zhang, Y.-Y.; Xie, N.; Sun, X.-D.; Nice, E.C.; Liou, Y.-C.; Huang, C.; Zhu, H.; Shen, Z. Insights and implications of sexual dimorphism in osteoporosis. *Bone Res.* **2024**, *12*, 8. [[CrossRef](#)]
36. Ganesan, M.; Eikenberry, A.; Poluektova, L.Y.; Kharbanda, K.K.; Osna, N.A. Role of alcohol in pathogenesis of hepatitis B virus infection. *World J. Gastroenterol.* **2020**, *26*, 883–903. [[CrossRef](#)]
37. Mota, A.; Guedes, F.; Areias, J.; Pinho, L.; Cardoso, M.F. Alcohol consumption among patients with hepatitis B infection in northern Portugal considering gender and hepatitis B virus genotype differences. *Alcohol* **2010**, *44*, 149–156. [[CrossRef](#)]
38. LeBoff, M.S.; Greenspan, S.L.; Insogna, K.L.; Lewiecki, E.M.; Saag, K.G.; Singer, A.J.; Siris, E.S. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos. Int.* **2022**, *33*, 2049–2102. [[CrossRef](#)]
39. Sampson, H.W. Alcohol's harmful effects on bone. *Alcohol Health Res. World* **1998**, *22*, 190–194.
40. Suárez Martínez, J.J. Hepatitis C virus infection and alcohol. *Ann. Hepatol.* **2006**, *5*, S58–S59. [[CrossRef](#)]
41. Lespessailles, E.; Toumi, H. Proton Pump Inhibitors and Bone Health: An Update Narrative Review. *Int. J. Mol. Sci.* **2022**, *23*, 10733. [[CrossRef](#)] [[PubMed](#)]
42. Donnelly, K.; Bracchi, R.; Hewitt, J.; Routledge, P.A.; Carter, B. Benzodiazepines, Z-drugs and the risk of hip fracture: A systematic review and meta-analysis. *PLoS ONE* **2017**, *12*, e0174730. [[CrossRef](#)] [[PubMed](#)]
43. Chew, K.W.; Bhattacharya, D.; McGinnis, K.A.; Horwich, T.B.; Tseng, C.-H.; Currier, J.S.; Butt, A.A. Short Communication: Coronary Heart Disease Risk by Framingham Risk Score in Hepatitis C and HIV/Hepatitis C-Coinfected Persons. *AIDS Res. Hum. Retroviruses* **2015**, *31*, 718–722. [[CrossRef](#)] [[PubMed](#)]

44. Cohen, J.F.; Ward, K.M.; Gittleman, J.; Perez, E.; Pia, T.; Shuter, J.; Weinberger, A.H.; Sulkowski, M. Hepatitis C and Cigarette Smoking Behavior: Themes From Focus Groups. *Nicotine Tob. Res.* **2024**, *26*, 1029–1037. [[CrossRef](#)]
45. Kim, R.S.; Weinberger, A.H.; Chander, G.; Sulkowski, M.S.; Norton, B.; Shuter, J. Cigarette Smoking in Persons Living with Hepatitis C: The National Health and Nutrition Examination Survey (NHANES), 1999–2014. *Am. J. Med.* **2018**, *131*, 669–675. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.